Akzo Nobel
To see an up-to date selection of historical analyses and insights on
Akzo Nobel,
visit our
new, dynamically updated Company Summary report pages for Akzo Nobel.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
Akzo Nobel are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
Akzo Nobel,
or on any other Company covered by EvaluatePharma® Contact Us today.
CONSENSUS FORECASTS ($US mln) - Sales Forecasts available to EvaluatePharma Subscribers
|
|
|
Annual Sales WW - Sales |
Growth per Year (%) |
|
|
Rank |
Product |
Generic Name |
Pharmacological Class |
2006 |
2007 |
2007 |
| Akzo Nobel |
1 |
Puregon/Follistim |
follitropin beta |
FSH |
482 |
489 |
|
1% |
|
|
|
2 |
Marvelon/ Desogen |
desogestrel & ethinyl estradiol |
Oestrogen & progestogen agonist |
307 |
308 |
|
0% |
|
|
|
3 |
NuvaRing |
etonogestrel & ethinyl estradiol |
Oestrogen & progestogen agonist |
268 |
302 |
|
13% |
|
|
|
|
|
Note: Shaded Cells |
|
|
|
|
FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
|
| Akzo Nobel |
|
|
2005 |
2006 |
| Valuation Measures |
| Based on Latest Share Prices |
| Valuing the Equity |
|
|
| Valuing the Enterprise |
| Free Cash Flow (Pre-Dividends) |
538 |
1,092 |
|
|
| Forecast Financials |
| Income Statement |
| Total Revenues |
16,173 |
17,259 |
| Cost of Goods Sold |
(8,777) |
(9,241) |
| S,G & A |
(4,978) |
(5,255) |
| R&D |
(1,038) |
(1,112) |
| Other Income/ Expense - Net |
46 |
(9) |
| Associate/ Equity Affiliate Income |
7 |
112 |
| EBIT - Normalised |
1,434 |
1,754 |
| Net Interest & Financial Items |
(188) |
(136) |
| Pre-tax Profits - Normalised |
1,247 |
1,618 |
| Exceptionals |
416 |
191 |
| Income Before Taxes |
1,662 |
1,809 |
| Tax |
(421) |
(324) |
| Tax Rate (%) |
25.3% |
17.9% |
| Minorities |
(46) |
(36) |
| Net Income - Reported |
1,196 |
1,449 |
| Net Income - Normalised |
925 |
1,324 |
|
|
| Per Share Data |
| EPS - Diluted |
4.17 |
5.02 |
| EPS - Basic |
4.18 |
5.06 |
| EPS - Normalised (diluted) |
3.23 |
4.59 |
| EPS - Normalised (basic) |
3.24 |
4.62 |
| Avg. Shares Outstanding - Diluted |
287.0 |
288.4 |
| Avg. Shares Outstanding - Basic |
285.8 |
286.5 |
| DPS |
1.42 |
1.59 |
|
|
|
IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
|
|
|
|
|
Product |
Generic Name |
| Akzo Nobel |
Almogran |
almotriptan |
|
|
Andriol |
testosterone undecanoate |
|
|
Anergix.RA/Org 42982 |
- |
|
|
Anzemet |
dolasetron |
|
|
Arduan |
pipecuronium bromide |
|
|
Arixtra |
fondaparinux sodium |
|
|
Atherosclerosis Project |
- |
|
|
Avinza |
morphine sulfate |
|
|
Bone Regeneration Project |
- |
|
|
Calderol |
calcifediol |
|
|
Cerazette |
desogestrel |
|
|
Clira |
desogestrel & ethinyl estradiol |
|
|
Cortrosyn |
cosyntropin |
|
|
Cyclessa |
desogestrel & ethinyl estradiol |
|
|
Dilena |
estradiol valerate & medroxyprogesterone acetate |
|
|
Durabolin |
nandrolone |
|
|
Eligard (SOT-375) |
leuprolide acetate |
|
|
Esmeron/Zemuron |
rocuronium bromide |
|
|
Exlutona |
lynestrenol |
|
|
Follegon |
follicle stimulating hormone |
|
|
GABA Modulator |
- |
|
|
Gracial |
desogestrel & ethinyl estradiol |
|
|
HumaSPECT |
votumumab |
|
|
Humegon |
menotropin |
|
|
IL-8 CXCR2 Receptor Antagonist |
- |
|
|
Immunomodulatory steroid |
- |
|
|
Implanon |
etonogestrel |
|
|
Insulin |
insulin |
|
|
Jenest |
ethinyl estradiol & norethindrone |
|
|
Laurina/Trimiron |
desogestrel & ethinyl estradiol |
|
|
Livial |
tibolone |
|
|
Lyndiol |
ethinyl estradiol & lynestrenol |
|
|
Male contraceptive (Org 3236+TU) |
etonogestrel & testosterone undecanoate |
|
|
Marvelon/ Desogen |
desogestrel & ethinyl estradiol |
|
|
Maxibolin |
ethylestrenol |
|
|
Megestron |
medroxyprogesterone |
|
|
Mercilon/ Mircette |
desogestrel & ethinyl estradiol |
|
|
Norcuron |
vecuronium bromide |
|
|
Normegon |
gonadotrophin stimulating hormone & luteinising hormone |
|
|
NuvaRing |
etonogestrel & ethinyl estradiol |
|
|
OncoTICE/Tice BCG |
mycobacteria |
|
|
Org 12962 |
- |
|
|
Org 23430 |
- |
|
|
Org 30659 |
tosagestin |
|
|
Org 33628/deso |
- |
|
|
Org 34850 |
- |
|
|
Org 37663 |
- |
|
|
Org 39141 |
ismomutin alfa |
|
|
Org 39479/PH 80 |
- |
|
|
Org 41259 |
- |
|
|
Org 41793 |
- |
|
|
Org 43553 |
- |
|
|
Org 43979 |
- |
|
|
Org 4419 |
mirtazapine (enantiomer) |
|
|
Org 4420 |
- |
|
|
Org 841 |
- |
|
|
Orgalutran/Antagon |
ganirelix |
|
|
Orgaran |
danaparoid sodium |
|
|
Ovestin |
estrogen |
|
|
Pavulon |
pancuronium |
|
|
Perselin |
allylestrenol |
|
|
Pregnyl |
human chorionic gonadotrophin |
|
|
Puregon/Follistim |
follitropin beta |
|
|
Raplon |
rapacuronium bromide |
|
|
Remeron |
mirtazapine |
|
|
Risperdal |
risperidone |
|
|
RO 60-0175 |
- |
|
|
Sandrena |
estradiol |
|
|
Teranas |
lomerizine |
|
|
Tolvon |
mianserin |
|
|
Variza |
gepirone |
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
